Article

Synovial fluid-derived mesenchymal stem cells increase after intra-articular ligament injury in humans

Section of Cartilage Regeneration, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Rheumatology (Oxford, England) (Impact Factor: 4.44). 09/2008; 47(8):1137-43. DOI: 10.1093/rheumatology/ken114
Source: PubMed

ABSTRACT The existence of mesenchymal stem cells (MSCs) in SF was previously reported. However, the behaviour and properties of MSCs derived from SF have not been fully elucidated.
Human SFs were obtained from 19 knee joints with anterior cruciate ligament injury around the time of reconstruction surgery, and from three healthy volunteers. SF was plated, cultured and examined for colony-forming number, in vitro differentiation, surface epitopes and gene profiles. Also, rabbit synovium-MSCs were injected into the knee joint in a rabbit partial anterior cruciate ligament defect model, and the injected cells were traced.
SF-MSCs from IA ligament injury patients were 100 times more in number than those from healthy volunteers. Total colony number was positively correlated with post-injury period. No significant differences were observed among the cells derived from SF around the time of the surgery in relation to surface epitopes and differentiation potentials. Cluster analysis of gene profiles demonstrated that SF-MSCs were more similar to synovium MSCs than bone marrow MSCs. In rabbit experiments, the MSCs injected into the knee in which IA ligament was partially defective were observed more on the defected area than on the intact area of the ligament at 24 h.
We demonstrated that SF-MSCs, similar to synovium MSCs, increased in number after IA ligament injury and surgery without marked alteration of the properties.

0 Followers
 · 
70 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) have the ability to differentiate into osteoblasts, chondroblasts, adipocytes, and even myoblasts. Most studies have focused on finding MSCs in different parts of the body for medical treatment. Every joint structure, including bone, joint fat, articular cartilage, and synovium, potentially contains resident MSCs. Recently, a progenitor cell population has been found in synovial fluid and showed similarities with both bone marrow and synovial membrane MSCs. Synovial fluid MSCs have been studied in healthy persons and osteoarthritic patients in order to explore its potential for treatment of some orthopedic disorders. Here, we briefly review the current knowledge on synovial fluid MSCs, their origin, relation to some orthopedic diseases, and future applications.
    Stem Cell Research & Therapy 10/2014; 5(5):112. DOI:10.1186/scrt501 · 4.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The possibility to isolate synovial fluid-derived mesenchymal stem cells (SFMSCs) from patients with degenerative arthropathy has been an interest since synovial fluid (SF) from osteoarthritis (OA) patients offered a unique stem-cell resource for therapeutic applications. In this study, we successfully isolated, cytogenetically and molecularly characterized, and followed the differentiation potency of human mesenchymal stem cells (MSCs) from SF. The morphology of proliferating SFMSCs showed fibroblast-like morphology, and both the population doubling time (DT) and viability of MSCs from bone marrow, adipose, and SF did not differ. The immunophenotype of SFMSCs was confirmed by the positive expression of CD44, CD73, CD90, CD105, and CD106 by flow cytometry and immunocytochemistry, and the expression of the hematopoietic markers, CD34 and CD45, was not found. In all MSCs from three different origins, we measured the mRNA expression of developmentally important transcript factors such as KLF4, c-Myc, Sox2, and OCT4. SFMSCs from OA patients showed normal chromosomal number, structure, and telomerase activity. SFMSCs showed multipotent capacity, and was differentiated into neurocyte, adipocyte, osteocyte, and chondrocyte in vitro, as demonstrated by specific stains and expression of molecular markers. In addition, SFMSCs also have the capacity to secrete immunomodulating factors (IL-4, IL-10, IL-13, and transforming growth factor-β (TGF-β)) involved in the therapy of rheumatoid arthritis (RA). These results demonstrate that SFMSCs from OA-patients might provide therapeutic options for RA and OA.
    Animal cells and systems the official publication of the Zoological Society of Korea 10/2013; 17(5):315-324. DOI:10.1080/19768354.2013.832705 · 0.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The in vitro differentiation and immunosuppressive capacity of mesenchymal stem cells (MSCs) derived from synovial fluid (SF-MSCs) and bone marrow extract (BM-MSCs) in an isogenic background of minipigs were comparatively analyzed in a collagen-induced arthritis (CIA) mouse model of rheumatoid arthritis (RA). The proliferation capacity and expression of pluripotent transcription factors (Oct3/4 and Sox2) were significantly (P<0.05) higher in SF-MSCs than in BM-MSCs. The differentiation capacity of SF-MSCs into adipocytes, osteocytes and neurocytes was significantly (P<0.05) lower than that of BM-MSCs, and the differentiation capacity of SF-MSCs into chondrocytes was significantly (P<0.05) higher than that of BM-MSCs. Systemic injection of BM- and SF-MSCs significantly (P<0.05) ameliorated the clinical symptoms of CIA mice, with SF-MSCs having significantly (P<0.05) higher clinical and histopathological recovery scores than BM-MSCs. Furthermore, the immunosuppressive properties of SF-MSCs in CIA mice were associated with increased levels of the anti-inflammatory cytokine interleukin (IL)-10, and decreased levels of the pro-inflammatory cytokine IL-1β and osteoclast-related sRANKL. In conclusion, SF-MSCs exhibited eminent pluripotency and differentiation capacity into chondrocytes, addition to substantial in vivo immunosuppressive capacity by elevating IL-10 and reducing IL-1β levels in CIA mice. Copyright © 2015. Published by Elsevier Inc.
    Experimental Cell Research 03/2015; 110. DOI:10.1016/j.yexcr.2015.03.015 · 3.37 Impact Factor

Full-text (2 Sources)

Download
59 Downloads
Available from
May 20, 2014